INTRODUCTION
Brain cancer survival rates have not changed significantly over the last 35 years, 1 and most forms of glioma remain refractory to current chemical, surgical, and radiation therapies. 2 Although oncolytic virus (OV)-based approaches to brain cancer treatment have enormous potential for success, it has thus far proven difficult to balance potent anti-tumor activity with safety when treating via direct intracranial (IC) infusion. Although certain OVs, such as those based on herpes simplex virus (HSV), can be infused safely into the cancer-bearing brain, there is typically little evidence of a radiographic anti-tumor response. [3] [4] [5] Conversely, other OVs, such as vesicular stomatitis virus (VSV), achieve robust anti-tumor efficacy in peripheral solid tumor models, 6, 7 but are generally extremely neurotoxic when injected directly into the brain. 8 We have previously generated the novel VSV mutant VSVD51 in an effort to improve VSV safety during oncolytic virotherapy. 9 This virus has a single amino acid deletion at position 51 of the VSV M protein that solidifies its therapeutic index by preventing viral blockade of host cell transcription and nucleocytoplasmic transport, including interferon (IFN) production. 9, 10 Following infection with VSVD51, non-malignant cells with intact IFN pathways are protected, whereas malignant cells, which have often lost the ability to mount an IFN response, remain largely susceptible. In mouse models of brain cancer, peripheral infusion of VSVD51 via the intravenous (i.v.) route allows the accumulation of virus at the brain tumor site in the absence of neurotoxic consequences, but few animals are successfully cured. 11 However, direct IC delivery of VSVD51 remains lethal. 12 This implies that VSVD51 can be safely tolerated in the brain if the initial location of virus sensing is in the periphery.
It has previously been shown that an extended period of repeat mucosal (intranasal [IN] ) or systemic [i.v.] immunizations with wild-type VSV can protect mice from subsequent IC challenge with the same virus. 12 This effect was predominantly mediated by adaptive cellular responses, including anti-viral antibodies and T cells. 12, 13 In our present study, we show that introducing virus in the periphery can activate an acute anti-viral response that conditions the brain to enable IC therapeutic application of an oncolytic virus in the absence of otherwise lethal consequences. Further, we demonstrate that this therapeutic approach can be used to successfully treat aggressive, syngeneic brain tumors. This concept may widen the treatment options available for oncolytic virus therapy in the brain. 
RESULTS

A Short Priming Exposure to VSVD51 in the Periphery Prevents Lethal CNS Effects when Virus Is Introduced into the Brain
In order to establish if acute pre-exposure to a low dose of systemic virus could condition mice to tolerate an otherwise lethal IC dose, mice were "primed" in the periphery with VSVD51-GFP and treated with an IC dose of VSVD51 expressing firefly luciferase (VSVD51-fLuc) at different times following the prime. This IC dose was 10 6 higher than the lethal dose. 12 The replication kinetics of the therapeutic (IC) virus were subsequently tracked by luciferase signal using IVIS imaging.
A CNS-protective effect established by the peripheral VSVD51-GFP prime was evident as early as 6 hr post-prime, with 67% of mice surviving a subsequent IC dose ( Figure 1A ). By 12 hr post-prime, 100% of VSVD51-primed mice were protected from the IC dose (Figure 1A) . By 96 hr post-prime, the IC dose was suppressed very rapidly in the brain ( Figure 1A ).
For many oncolytic virus platforms, a degree of virus replication appears to be a necessary requirement for efficacy. [14] [15] [16] [17] Since IC treatment at 24 hr post-prime allowed virus replication but ultimately safely controlled IC viral loads, we further explored this priming schedule in subsequent experiments ( Figure 1B) . We established that luciferase activity from the replicating IC-delivered virus, as measured by total photon flux, was directly correlated with virus titers in the brain ( Figure 1C ; see also Figure S1 ). Ultimately, all VSVD51-primed animals survived an otherwise uniformly lethal IC dose, whereas all PBS-primed animals succumbed to encephalitis ( Figure 1D ). This effect was observed in both male and female animals and was maintained across multiple strains of mice, including C57BL/6, FVBN, and BALB/c ( Figure 1D ; see also Figure S2 ).
Route of Peripheral Priming Impacts Viral Clearance and Protection in the CNS
To establish if the route of peripheral priming had an impact on the clearance of IC virus from the brain and survival outcomes, mice were primed with VSVD51-GFP for 24 hr via intraperitoneal (i.p.), intramuscular (i.m.), i.v., IN, or subcutaneous (s.c.) routes. Subsequently, animals received an IC dose of VSVD51-fLuc.
Intraperitoneal priming resulted in the most efficient clearance of virus from the brain following IC treatment, with a more rapid reduction in viral loads in the brain compared to other routes (p < 0.001 at 48 hr) (Figure 2A ). Other routes of administration, including i.m., IN, i.v., and s.c., achieved similar rates of VSVD51-fLuc clearance from the brain post-IC treatment. However, only priming through i.p., i.v., and i.m. routes provided complete protection from the otherwise lethal neurotoxic consequences following IC treatment ( Figure 2B ).
Peripheral Priming Reduces but Does Not Prevent VSVD51 Infection in the Brain
In order to determine the impact of priming on the behavior of virus in the brain, we analyzed VSVD51-fLuc localization and infection following IC treatment in VSVD51-primed or control animals. Viral antigen was analyzed in the brain by immunohistochemistry or immunofluorescence at different time points following IC treatment. Overall, less viral antigen was evident in the brains of VSVD51-primed animals compared to mock-primed animals following IC treatment. At 24 hr post-IC, viral antigen was detected around the ventricles and hippocampus in the brains of mock-primed mice but was largely confined to the ventricles in animals primed with VSVD51 ( Figure 3A) . By 72 hr post-IC treatment, virus had spread extensively throughout the hippocampus and midsection near the lateral ventricle in mock-primed animals, whereas in VSVD51-primed mice, virus remained restricted to the lateral ventricle, with relatively minimal viral antigen loads detected in the hippocampus ( Figure 3A) . By 96 hr, viral antigen had spread from the lateral ventricle (LV), third ventricle (3V), and dorsal third ventricle (D3V) into the hippocampus, thalamus, striatum, and fourth ventricle (4V) in mock-primed animals. However, in VSVD51-primed mice, virus continued to be contained within discrete areas at relatively low levels, with no spread into 4V (Figure 3A) . No viral antigen was detected in the brains of mice receiving a VSVD51-GFP priming dose alone (no IC treatment) (data not shown).
At the cellular level, viral antigen co-localized with neuronal markers (NeuN + ) in both VSVD51-primed and mock-primed mice (Figure 3B ). However, in unprotected mock-primed animals, robust virus-associated fluorescence was observed in both the cell body and neurites, suggesting a fulminant infection. In protected VSVD51-primed animals, low levels of virusassociated fluorescence were confined to the cell body. Viral antigen could not be detected within microglia/endothelia (RCA-1 + ) or astrocyte (GFAP + ) populations in the brains of either group of animals ( Figure 3B ), consistent with previous reports. 18 Thus, peripheral priming with VSVD51-GFP did not alter viral cellular specificity, but had a profound impact on limiting VSVD51-fLuc viral replication and spread throughout the brain.
Adaptive Immune Responses Have a Limited Contribution to Peripheral Priming-Induced Protection in the Brain
We analyzed the contribution of adaptive immune responses to the protective benefits conferred by our peripheral prime. Neither T cells nor B cells were observed to infiltrate the brain at early time points following IC treatment (see Figure S3 ). T cells were detectable by 6 days post-IC treatment in the brains of both PBS-and VSVD51-primed mice (see Figure S3 ), whereas B cells remained absent at this time point (see Figure S3 ). Interestingly, a substantial infiltration of cells with a phenotype consistent with a granulocytic/monocytic origin (CD45 + CD11b + Gr-1 + cells) was observed in the brain of PBS-primed animals at 12 hr following IC VSVD51-fLuc treatment. However, this population was absent in the brains of VSVD51-primed animals (see Figure S4 ). We also observed an increase in the expression of toll-like receptor 2 (TLR2) in a microglial cell population defined as CD45 lo CD11b + Gr-1 À in the brains of mice receiving a peripheral VSVD51 prime compared to control animals (see Figure S4 ), consistent with the establishment of a pro-inflammatory state that can protect against a lytic virus infection. 19 This upregulation of TLR2 was largely driven by the peripheral virus dose (see Figure S4 ), further supporting the concept that the peripheral prime conditioned the brain to facilitate viral control.
The contribution of T cells to the protective effect of the VSVD51 prime was further assessed in nude mice, which lack mature T cells. VSVD51-primed nude mice controlled viral titers in the brain following IC treatment (Figures 4A and 4B) and were fully protected from CNS lethality ( Figure 4C ). Since B cells have been reported to have a role in mediating anti-viral effects following VSV infection in the periphery, 20 we further assessed their contribution in our model using u-chain-deficient mice, which lack mature B cells. Following a peripheral VSVD51-GFP prime, u-chain-deficient mice controlled VSVD51-fLuc viral replication after IC treatment, and all animals survived ( Figure 4D and data not shown). Thus, neither T cells nor B cells were critical to allowing peripherally primed mice to clear IC-administered virus in the acute therapeutic time frames established in our model. Finally, we explored the potential contribution of virus-neutralizing antibodies to the protective effect observed in our prime/treat model. Serum isolated from VSVD51-primed animals at 48 hr but not 24 hr post-prime was able to reduce VSV infectivity in susceptible target cells above the negative control ( Figure 4E ). Thus, at the time of IC treatment (24 hr post-prime), there was no evidence of VSV-neutralizing activity in the blood, suggesting that antibodies did not contribute to the priming effect in our model.
IFNs Are Beneficial, but Not Sufficient, to Mediate Protection during IC Virus Therapy
The rapid induction of protection in the brain within hours following a peripheral VSVD51 prime suggested the involvement of innate rather than adaptive immune mechanisms. Although wild-type VSV can block IFN production to evade immune responses during host cell infection, the VSVD51 mutant is much less potent in its ability to impact host immune pathways. Indeed, host cell soluble factors, including type I IFNs, appear in the serum shortly after VSVD51 infection 9 and play an important role in limiting local and systemic spread. 21, 22 In order to explore the possibility that innate factors in the serum had a role in the early brain-protective effects observed following a VSVD51 peripheral prime, we isolated serum, splenocytes, and lymph nodes from VSVD51-primed mice at 6 hr post-prime. We determined if i.p. passive transfer of these isolated tissue fractions into naive mice could establish protection against an IC dose of VSVD51-fLuc. Transfer of serum but not splenocytes or lymph nodes isolated from 6 hr VSVD51-primed mice could control virus in the brain following IC treatment and ultimately protected mice from otherwise lethal CNS consequences ( Figure 5A and data not shown). Serum isolated from mice primed with VSVD51 for 24 hr failed to control IC virus loads and did not protect mice ( Figure 5A ). This suggested that a protective factor(s) was present in the serum during a short window (<24 hr) following a peripheral VSVD51 prime.
We interrogated serum and cerebrospinal fluid (CSF) at 6 or 12 hr in animals who had received a single dose of VSVD51-GFP in the periphery (i.p.) versus directly in the brain (IC) for the presence of IFNa, IFNb, or IFNg by ELISA. At 6 hr, all three IFNs were detectable in the serum of mice receiving an i.p. VSVD51-GFP prime, with levels declining by 12 hr ( Figure 5B ). In the CSF, only IFNa was detectable at 6 hr post-i.p. prime, declining below the limit of detection by 12 hr ( Figure 5B ). In mice receiving VSVD51-GFP directly into the brain, low or undetectable levels of all three cytokines were evident at 6 hr in the serum or CSF ( Figure 5B ). However, levels of IFNg increased in the serum at 12 hr, whereas levels of IFNb increased in the CSF at 12 hr, consistent with the previously defined role of IFNb as a key protective type I IFN produced locally in the brain. [23] [24] [25] Taken together, this suggested that the kinetics of IFN production during a primary IC infection may have been too slow to adequately control virus in the brain; however, the administration of virus via the i.p. route achieved an early peak in IFNs.
Since all three detected IFNs play a role in modulating blood-brain barrier (BBB) permeability [26] [27] [28] and contribute to the anti-VSV response in intranasal infection models, 25, 29 we proceeded to further investigate their contribution to CNS protection in the prime/treat setting. To do this, we introduced each individual cytokine exogenously as a "prime" (in the absence of virus), followed by IC application of VSVD51-fLuc. IFNb or IFNg were administered IC because they are typically produced locally in the brain during infection, 23 whereas IFNa, typically considered a peripheral cytokine with limited penetrance across the BBB, 30 was administered i.p. at doses known to block peripheral VSV infection. 31 Mice primed with IFNa had no benefit in terms of viral control or survival following IC treatment ( Figure 5C ). Similarly, administering IFNb as an exogenous prime had no protective effect ( Figure 5C ). Priming with exogenous IFNg recapitulated the protection conferred by the VSVD51 prime, both in terms of replication control and survival (p < 0.05) ( Figure 5C ). However, VSVD51-priming in IFNg À/À transgenic knockout mice controlled IC virus loads (see Figure S5 ) and provided complete protection, whereas all mock PBS-primed mice succumbed to lethal encephalitis (see Figure S5 ). This suggested that IFNg could be protective, but did not appear to be absolutely required within the context of our prime/treat model. As an extended experimental approach, we aimed to knock out type I IFNs in the www.moleculartherapy.org prime/treat setting by using either antibody-mediated blockade in wild-type mice or transgenic IFNAR À/À mice. However, the priming dose of virus alone was lethal in both settings, rendering these experiments untenable. This included priming with VSVD51-GFP or VSVD51-Gless (which can undergo VSV-G-mediated cell entry but is only capable of a single-round of infection and is protective in the prime/treat setting in wild-type mice); UV-inactivated VSVD51-GFP was also considered as a prime but failed to protect in wild-type mice and was thus discarded. Finally, priming animals with other viruses capable of inducing type I IFN responses, such as reovirus, 32 or innate immune stimulators, such as lipopolysaccharide (LPS) or the TLR7 agonist loxoribine, 33 also failed to control IC VSVD51 loads and failed to protect mice (see Figure S6) . Thus, IFNs appeared to be necessary but not sufficient as standalone mediators of protection in our model.
Peripheral VSVD51 Priming Allows Effective IC Oncolytic Treatment in Syngeneic Gliomas
We evaluated the therapeutic relevance of the VSVD51 prime/treat regime in the aggressive orthotopic syngeneic CT2A glioma model. CT2A astrocytoma cells expressing fLuc were seeded intracranially in C57BL/6 mice. Following priming and IC treatment, approximately 20% of CT2A tumor-bearing mice responded with complete tumor regression, as monitored through fLuc expression ( Figures  6A and 6B ). Mice that initially responded to the prime/treat regime survived and remained tumor free ( Figures 6A and 6B ). Mice that did not respond to the prime/treat regime succumbed due to tumor complications, including weight loss and neurological symptoms. Priming with VSVD51 alone in the absence of a subsequent therapeutic IC dose did not have a significant impact on survival compared to PBS controls ( Figures 6A and 6B ).
DISCUSSION
We have developed a novel strategy for oncolytic virus therapy in the brain that appears to harness an early warning system that can protect from the otherwise lethal encephalitic effects of a rhabdovirus penetrating into the CNS. From a therapeutic perspective, this provides a window of opportunity in which peripheral host responses can be sufficiently engaged to protect against neurotoxicity by rendering the normal brain resistant to an IC therapeutic dose of virus while simultaneously maintaining tumor susceptibility to viral oncolytic effects. Ultimately, this prime/treat approach creates a therapeutic index that allows the application of a loco-regional viral therapy to achieve cures in an aggressive syngeneic glioma model.
VSV induces a myriad of host immune responses in the first 24 hr following infection. 34 This includes the long-distance activation of an IFN-independent anti-viral state in uninfected cells of the brain following systemic infection. 25 Extended (6 week) peripheral immunization regimes have previously been shown to enable the direct IC infusion of attenuated VSV mutants without lethal consequences, highlighting a role for adaptive immunity and neutralizing antibodies in the control of VSV over longer therapeutic time frames. 12 Yet the rapid ability of a priming dose to control IC VSVD51 replication in our model was fully established by 12 hr and was maintained in the absence of mature T cells (in nude mice) or mature B cells (in u-chain-deficient mice). We were unable to detect virus-neutralizing antibodies earlier than 48 hr following the peripheral VSVD51 prime, similar to previous reports. 29, [35] [36] [37] Further, our observations that an IC challenge at 96 hr post-prime severely limited virus replication in the brain suggested that sterilizing immunity was established around 96 hr following the initial priming exposure, which is in line with previous reports. [38] [39] [40] Collectively, this implied that B cells (including neutralizing antibodies) and T cells were not overtly involved in the early and rapid protective effects conferred by the peripheral VSVD51 prime. This does not exclude their contribution at later stages of virus replication in solidifying CNS protection, as previously reported. 41, 42 Peripheral priming with VSVD51 reduced the spread of IC virus through the brain and did not alter viral tropism following IC treatment, with VSV antigen co-localizing with neuronal populations, as previously observed. 43 Importantly, there was no evidence of neurological dysfunction in the prime/treat model, suggesting that this approach was clinically tractable.
Serum isolated from 6 hr VSVD51-primed mice conferred protection against IC virus in naive animals, whereas 24 hr primed serum was not protective. This suggested that a soluble factor(s) in the serum may be mediating the protective effect. Interestingly, the protection conferred by passive transfer was transient, whereas the protection achieved by natural infection in the periphery appeared to be relatively long lasting. We hypothesize that in vivo, the natural course of peripheral infection likely establishes depots of viral antigen that persist following the resolution of VSVD51 infection and contribute to ongoing, low-level immune system stimulation, as previously described. 44, 45 This likely sustains the protective effect over an extended period of time. However, in the case of the passive transfer of serum, which has been treated to remove infectious virus, protective factor(s) are undoubtedly present in a finite amount, and these immune resources are likely rapidly consumed. Elevated levels of IFNa, IFNb, and IFNg were present at 6 hr in the serum of i.p. VSVD51-primed mice, a time point when we observed the majority of mice ($67%) to be protected from a subsequent IC challenge, with concentrations of these cytokines declining by 12 hr post-prime. Indeed, the rapid production of IFNb we observed following the peripheral VSVD51 prime, which has previously been shown for other rhabdoviruses, 46 may have been responsible for the block in (negative control). At 24 hr post-prime, mice received an IC dose of 2 Â 10 7 PFU VSVD51-fLuc. IC virus replication was tracked by luminescence using IVIS imaging (left), and corresponding survival data were captured (right) based on 3 mice per group. Dotted line represents background luminescence. Statistical analysis of survival curves was performed using the log-rank (Mantel-Cox) test relative to PBS. *p < 0.05; **p < 0.01; ns, no significance. Error bars refer to SD.
granulocyte infiltration into the brain that we observed following peripheral priming. 47 Such a reduction in granulocytic infiltration can dampen pathological inflammation and promote oncolytic safety as granulocytes contribute to the development of viral encephalitis but do not affect viral clearance. 48 After testing the contribution of individual IFNs to the protective effect by administering them as an exogenous prime prior to IC virus administration, we concluded that neither IFNa nor IFNb alone was sufficient to orchestrate protection because i.p. or IC delivery of these cytokines, respectively, failed to recapitulate the benefits of a VSVD51 prime. Of note, IFNg was capable of achieving protection in the brain because its exogenous administration as a local IC "prime" 6 hr prior to VSVD51 IC treatment controlled viral loads in the brain and achieved complete protection, similar to the VSVD51 peripheral prime itself. Indeed, other groups have demonstrated that IFNg can protect neurons from VSV infection. [49] [50] [51] Yet because IFNg knockout mice could be protected with a VSVD51 prime to the same degree as wild-type mice, this suggested a redundant role for IFNg in our model. Other groups have also shown that systemic IFNg contributes to but is not essential for local clearance of VSV in the brain. 52 Interestingly, our attempts to utilize other viruses or "virus-like" danger signals by priming with reovirus or innate immune stimulators, such as LPS or loxoribine, were similarly unable to confer protection against IC VSVD51 treatment. Here, we have described a mechanism that allows VSVD51 to be tolerated in both the normal and tumor-bearing brain. This mechanism can be exploited to improve the safety of oncolytic virus therapy by initiating an anti-viral state through a short peripheral exposure to virus, thereby enabling the IC administration of therapeutically relevant doses (over 10,000 times more virus particles than have been previously reported 12 ) of a normally neurotoxic virus to treat brain cancer. Importantly, this approach achieved successful cures in an aggressive, syngeneic glioma model with a single IC dose of VSVD51. These findings have clear translational relevance because work in our laboratory suggests that the outcome of oncolytic virotherapy in the brain may be enhanced when virus is delivered by dual i.v. and IC routes (unpublished observation). The approach we have described may guide the development of similarly clinically tractable strategies to treat CNS malignancies with other extremely potent oncolytic viruses, such as Maraba virus. 6, 7 Future studies that determine the precise combination of innate factors that contribute to CNS protection will prove useful for guiding new interventions aimed at preventing diseases affecting the brain.
MATERIALS AND METHODS
Mice 6-to 8-week-old BALB/c, C57BL/6, FVBN, and nude mice were purchased from Charles River Canada (Constant, QC, Canada). IFNg knockout (BALB/c-Ifgtml), IFNAR knockout (C57BL/6-129S2-Ifnar1tm1Agt/Mmjax), and mu-chain deficient (C57BL/6-129S2-Ighmtm1Cgn/J) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were kept in sterile isolation cages and maintained on a 12-hr dark-light cycle. To establish the CT2A astrocytoma model, 53 ,54 C57BL/6 mice were injected sterotactically with 10 5 CT2A-fLuc cells. All animal procedures were performed in accordance with the institutional guidelines of the University of Ottawa committee on the Use of Live Animals in Teaching and Research.
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Viruses and Infections
The VSVD51-GFP (Indiana serotype), VSVD51-GFP-fLuc (herein referred to as VSVD51-fLuc), and VSVD51 no reporter (VSVD51-NR) viruses were provided courtesy of Dr. John Bell (OHRI, Canada). Unless otherwise stated, mice were primed intravenously with 1 Â 10 8 plaque forming unit (PFU) (BALB/c) or 5 Â 10 8 PFU (C57BL/6) of VSVD51-GFP or PBS as a control. Unless otherwise stated, mice were treated intracranially with 2 Â 10 7 PFU VSVD51-fLuc or VSVD51-NR using stereotactic injection into the striatum. Mice were monitored daily by weight and euthanized at endpoint (neurological symptoms or loss of >20% of initial body weight). Reovirus (type 3 Dearing) was administered i.p. at a sub-lethal dose of 10 8 PFU.
IVIS Imaging
Luciferase-expressing virus or CT2A-Luc astrocytomas were detected by optical in vivo imaging using the Xenogen IVIS-200 system. Mice were anesthetized by isofluorane and injected i.p. with 4 mg of luciferin (Molecular Imaging Products) 5 min prior to imaging. Images were processed and analyzed using Living Image 3.1 software (Xenogen). Flux curves were plotted as mean with SD, unless otherwise indicated.
ELISA CSF was collected from the cisterna magna. Serum was isolated from whole blood by centrifugation at 10,000 Â g. IFNa and -b were assayed in CSF and serum by ELISA (PBL Biomedical Laboratories) using a Spectramax 340 PC automated plate reader at 450 nm. Data were acquired using Softmax Pro 4.7.1 (Molecular Devices).
Soluble Priming Treatments
BALB/c mice were injected i.p. with 20,000 U IFNa or PBS 24 hr prior to receiving an IC dose of VSVD51. Two additional doses of 10,000 U IFNa were administered i.p. just prior to IC dosing and at 24 hr post-IC dosing. Exogenous IFNb was administered at 10,000 U IC 6 hr prior to IC treatment. Exogenous IFNg was administered at 50,000 U IC 6 hr prior to IC treatment. Loxoribine was administered i.p. at 2 mg per mouse, and LPS was administered i.p. at 1 mg/kg.
For serum, spleen, and lymph node fraction adoptive transfers, organs were harvested from animals primed with 1 Â 10 8 PFU VSVD51-GFP at 6 or 24 hr (serum only) post-prime. Serum was isolated as above. Spleens or lymph nodes were manually homogenized, dissociated, and passed through a 2 mm filter to prepare pooled bulk splenocytes or lymph node homogenates, respectively. Each dissociated organ preparation was incubated with anti-VSV(G) (a gift from Dr. E. Brown, University of Ottawa) and run through a Protein G column to precipitate antibody-associated virus. Plaque assays were performed to verify that no infectious virus was present before adoptive transfer.
Virus Neutralization Assay
Serum samples were isolated as described above, diluted 1:100, and incubated with serial dilutions of VSVD51 for 1 hr at 37 C prior to plating on confluent Vero cells. After 1 hr, VSV-infected Vero cells were overlaid with a 1:1 mixture of 2ÂaMEM containing 20% fetal calf serum (FCS) and agarose. Plaques were counted after 24 hr.
Immunohistochemistry
Mice were anesthetized with a lethal dose of sodium pentobarbital and trans-cardially perfused with PBS. For frozen sections, mice were subsequently perfused and brains were isolated in 4% paraformaldehyde (PFA) followed by 20% sucrose and then flash frozen in liquid nitrogen. 10 mm horizontal or sagittal sections were cut and mounted on Superfrost Plus (Fisher Scientific) glass slides. For paraffin sections, fresh brains were transferred into 10% phosphatebuffered formalin followed by 70% EtOH and paraffin embedding. 5 mm sections were mounted onto glass slides. Sections were de-paraffinized and antigen retrieval was performed in sodium citrate buffer. Sections were incubated with 3% hydrogen peroxide and blocked in 5% serum for 1 hr at room temperature (RT). Slides were incubated with primary antibody (anti-CD3ε [BD Biosciences], anti-CD45R/B220 [BD Biosciences], or anti-VSV(G) [a gift from Dr. E. Brown, University of Ottawa]) for 2 hr, followed by a biotinylated secondary antibody (BD Biosciences) for 30 min at RT. AvidinBiotin-Peroxidase (ABC Kit, Vector Laboratories) was applied as per the manufacturer's protocol. 3,3'-Diaminobenzidine (DAB; Sigma) was added for 2 min before immersing in ddH2O and counterstaining with hematoxylin, followed by slide mounting in xylene medium. Sections were scanned using a UMAX Astra 1220S scanner. Sections were viewed using Zeiss Axioskop 2 mot (Carl Zeiss Canada) fitted with a QICAM digital CCD camera (Qimaging). Northern Eclipse software (EMPIX Imaging) was used to acquire all images.
Flow Cytometry
Brains were isolated and homogenized, and single-cell suspensions were prepared by filtration through a 100 mm mesh. Cellular infiltrates were stained with anti-CD45.2 (clone 104, BD Biosciences), anti-CD11b (clone M1/70, BD Biosciences), anti-Ly-6G/Ly-6C (clone RB6-8C5, BD Biosciences), and/or TLR2 (clone 6C2, eBioscience), and acquired on a FACS Canto (BD Biosciences) running DIVA software. 
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